ArticleThorax2005
Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia.
Article in Thorax, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Multidrug resistant tuberculosis in prisons located in former Soviet countries: A systematic review.PloS one · 2017Pooled it
- Prisoners co-infected with tuberculosis and HIV: a systematic review.Journal of the International AIDS Society · 2016Pooled it
- Pooled it
- Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis.PloS one · 2010Trial
- Prevalence, drug-susceptibility pattern and associated factors ofIJID regions · 2023Article
- Planning and development of an antimicrobial stewardship program in penitentiary facilities: strategies to optimize therapeutic prescribing and reduce the incidence of antibiotic resistance.Frontiers in public health · 2023Article
- Tuberculosis Notification Trends and Treatment Outcomes in Penitentiary and Civilian Health Care Sectors in the WHO European Region.International journal of environmental research and public health · 2021Article
- Prevalence and Determinants of Multidrug-Resistant Tuberculosis in Makkah, Saudi Arabia.Infection and drug resistance · 2020Article
- Article
- Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.The Lancet. Infectious diseases · 2019Review
- Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis.BMC medicine · 2018Article
- Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia.BMC infectious diseases · 2018Article
- Association between tobacco smoking and drug-resistant tuberculosis.Infection and drug resistance · 2018Review
- Drug resistant tuberculosis in Saudi Arabia: an analysis of surveillance data 2014-2015.Antimicrobial resistance and infection control · 2018Article
- Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.BMC infectious diseases · 2017Observational
- Prevalence and Associated Factors of Tuberculosis in Prisons Settings of East Gojjam Zone, Northwest Ethiopia.International journal of bacteriology · 2017Article
- Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada.PloS one · 2017Article
- Smear positive pulmonary tuberculosis and HIV co-infection in prison settings of North Gondar Zone, Northwest Ethiopia.BMC public health · 2016Article
- Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in Pakistan.PloS one · 2016Article
- A smoking cessation intervention among tuberculosis patients in rural China.Public health action · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) and HIV rates continue to escalate in Russia, but true rates for drug resistance, especially multidrug resistant tuberculosis (MDR TB), are unknown. A study was conducted with the aims of identifying first line drug resistance, both in the civilian and prison sectors, for new and previously treated cases; and risk factors for the development of drug resistance.
methodsA cross sectional survey was undertaken of 600 patients (309 civilians, 291 prisoners) with bacteriologically confirmed pulmonary TB over a 1 year period during 2001-2 in Samara Oblast, Russia.
resultsThe prevalence of isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide resistance in new TB cases (civilian and prison patients) was 38.0%, 25.2%, 34.6%, 14.7%, and 7.2%, respectively. The prevalence of MDR TB was 22.7%, 19.8%, and 37.3% in all new cases, new civilian cases, and new prison cases, respectively, with an overall prevalence of 45.5% and 55.3% in previously treated cases. Factors associated with resistance included previous TB treatment for more than 4 weeks, smoking (for isoniazid resistance), the presence of cavitations on the chest radiograph, and imprisonment. HIV was not associated with resistance in all patients. The rates of resistance were significantly higher in prisoners, with rate ratios (RR) of 1.9 (95% CI 1.1 to 3.2) for MDR TB, 1.9 (95% CI 1.1 to 3.2) for rifampicin, and 1.6 (95% CI 1.0 to 2.6) for isoniazid.
conclusionsRates of first line drug resistance are high, particularly in prisoners and previously treated cases. TB control programmes should initially focus on standardised treatment to maximise cure, combined with measures to reduce institutional TB spread (particularly in prisons) coupled with early diagnosis of MDR TB to reduce the spread and development of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.